Compare BRTX & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRTX | ADVB |
|---|---|---|
| Founded | 1997 | 2014 |
| Country | United States | United States |
| Employees | N/A | 31 |
| Industry | Managed Health Care | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 109.2M |
| IPO Year | 2015 | N/A |
| Metric | BRTX | ADVB |
|---|---|---|
| Price | $0.28 | $5.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 7.3M | 199.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 66.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $81,000.00 | N/A |
| Revenue This Year | $24.64 | N/A |
| Revenue Next Year | $287.76 | N/A |
| P/E Ratio | ★ N/A | $1.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.19 | $0.19 |
| 52 Week High | $2.10 | $5.82 |
| Indicator | BRTX | ADVB |
|---|---|---|
| Relative Strength Index (RSI) | 30.61 | 85.14 |
| Support Level | $0.19 | $0.41 |
| Resistance Level | $0.29 | $5.75 |
| Average True Range (ATR) | 0.03 | 0.69 |
| MACD | 0.04 | 0.12 |
| Stochastic Oscillator | 82.04 | 71.04 |
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.